These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31589122)

  • 1. Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease.
    Qiu L; Guo C
    Curr Drug Targets; 2020; 21(6):599-609. PubMed ID: 31589122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.
    Chen T; Shi D; Chen J; Yang Y; Qiu M; Wang W; Qiu L
    Mol Med Rep; 2015 Jan; 11(1):303-8. PubMed ID: 25333350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.
    Qiu LX; Chen T
    World J Gastroenterol; 2015 Jan; 21(4):1099-107. PubMed ID: 25632182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Compounds with Aldose Reductase (AR) Inhibition: A Class of Medicative Agents for Fatty Liver Disease.
    Wang T; Xu ZH
    Comb Chem High Throughput Screen; 2023; 26(11):1929-1944. PubMed ID: 36655533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibitor protects mice from alcoholic steatosis by repressing saturated fatty acid biosynthesis.
    Guo C; Chen L; Huang J; Wang Y; Shi C; Gao J; Hong Y; Chen T; Qiu L
    Chem Biol Interact; 2018 May; 287():41-48. PubMed ID: 29630881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose Reductase Inhibitors of Plant Origin in the Prevention and Treatment of Alcoholic Liver Disease: A Minireview.
    Qiu L; Guo C; Hua B
    Biomed Res Int; 2019; 2019():3808594. PubMed ID: 31321234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
    Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
    J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.
    Shi C; Wang Y; Gao J; Chen S; Zhao X; Cai C; Guo C; Qiu L
    Mol Med Rep; 2017 Sep; 16(3):2767-2772. PubMed ID: 28677809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.
    Sanchez-Lozada LG; Andres-Hernando A; Garcia-Arroyo FE; Cicerchi C; Li N; Kuwabara M; Roncal-Jimenez CA; Johnson RJ; Lanaspa MA
    J Biol Chem; 2019 Mar; 294(11):4272-4281. PubMed ID: 30651350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice.
    Qiu L; Lin J; Xu F; Gao Y; Zhang C; Liu Y; Luo Y; Yang JY
    Exp Diabetes Res; 2012; 2012():789730. PubMed ID: 22110479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous Extract of Pepino (
    Hsu JY; Lin HH; Hsu CC; Chen BC; Chen JH
    Nutrients; 2018 Jul; 10(7):. PubMed ID: 30037014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Human Alcoholic Liver Disease.
    Wang M; Chen WY; Zhang J; Gobejishvili L; Barve SS; McClain CJ; Joshi-Barve S
    Hepatology; 2020 Nov; 72(5):1617-1637. PubMed ID: 32086945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.